Session » Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA

Date: Sunday, November 13, 2022

Time: 3:00PM-4:30PM

Meeting: ACR Convergence 2022

3:00PM-4:30PM: Abstract Number: 1597

Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

3:00PM-4:30PM: Abstract Number: 1599

Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

3:00PM-4:30PM: Abstract Number: 1601

Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial

3:00PM-4:30PM: Abstract Number: 1602

Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis

3:00PM-4:30PM: Abstract Number: 1598

Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

3:00PM-4:30PM: Abstract Number: 1600

The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

« View all sessions from this meeting